Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOndine Biomed Regulatory News (OBI)

Share Price Information for Ondine Biomed (OBI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.50
Bid: 7.00
Ask: 8.00
Change: -0.75 (-9.68%)
Spread: 1.00 (14.286%)
Open: 7.75
High: 7.75
Low: 7.00
Prev. Close: 7.75
OBI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ondine receives funding for meat photodisinfection

5 Dec 2022 07:00

RNS Number : 5216I
Ondine Biomedical Inc.
05 December 2022
 

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine receives funding for meat photodisinfection

· Funding of up to $735,000 towards development of prototype of novel photodisinfection application for use in food production.

· Up to 30% of food is lost due to degradation according to the UN.[1]

· Photodisinfection kills all types of pathogens - viruses, bacteria, and fungi - without creating resistance.

Ondine Biomedical Inc. (LON:OBI): Canadian life sciences company, Ondine Biomedical, has received funding of nearly $735,000 from Agriculture and Agri-Food Canada (AAFC) towards development of a food-safe photodisinfection method for Canada's meat packing industry. Ondine will leverage its proven medical photodisinfection technology platform to create a novel, photodynamic disinfection process to destroy pathogens on meat products without causing microbial resistance.

The Canadian meat processing industry has an urgent need for the development of technologies to reduce the incidence of food-borne pathogens including bacteria, fungi, viruses, and protozoa. Eradicating these invasive microbes will help protect the $9.4 billion (2021) Canadian meat export industry, as well enhance as the lives and welfare of Canadian consumers by reducing the incidence of food-borne illnesses.

Pathogens, such as Staphylococcus aureus and MRSA, are known to spread easily in meat packing facilities, especially in the pork industry.[2] Reducing the spread of these deadly pathogens is critical not only for consumer safety but also for that of the employees and the livestock at these facilities. Photodisinfection is highly effective against these pathogens, with recent research showing that Ondine's technology eliminated more than 99.9% of S. aureus in only 60 seconds, irrespective of the pathogen's level of antibiotic resistance[3].

Dr. Nicolas Loebel, President and Chief Technology officer of Ondine Biomedical Inc. said:

"Approximately 3.5 billion kilograms of poultry and meat are wasted every year globally, with a significant portion of this due to microbial spoilage. The related costs of beef spoilage alone in Canada are estimated at $200 million per year. Our innovative, rapid, and inexpensive approach to broad-spectrum disinfection has been proven both safe and effective for over a decade in Canadian hospitals, allowing tens of thousands of patients to reduce their risk of an antibiotic-resistant surgical site infection. Recognizing the impact of antibiotic resistance in the meat packing industry, we realized that we could deploy the same technology in food safety - eliminating tough, food-borne pathogens which can undermine the health and safety of all Canadians. We are delighted to be recognized by Agriculture and Agri-Food Canada as a key contributor in their fight against this problem and believe we are uniquely positioned to develop an effective solution."

The Honourable Marie-Claude Bibeau, Minister of Agriculture and Agri-Food:

"Processors across the country are committed to providing safe and high-quality products to Canadians. Innovative technology helps processors achieve this standard, as it provides solutions to problems, increases productivity and maintains efficacy. The Government of Canada is committed to investing in projects that keep our food safe over the long-term."

The Honourable Hedy Fry PC Member of Parliament for Vancouver Centre, British Columbia:

"I commend Ondine for all it's accomplished, not only here in Vancouver, but on behalf of Canadians. The company is helping establish a reliable technology that can keep meat safe for consumers, now and in the future. Today's investment will help Ondine continue its work, provide guidance and support the agriculture sector's long-term growth."

The project announced today is funded in part by the Government of Canada under the Canadian Agricultural Partnership's AgriScience Program, a federal, provincial, territorial initiative. The AgriScience Program aims to accelerate the pace of innovation by providing funding and support for pre-commercial science activities and cutting-edge research that benefits the agriculture and agri-food sector and Canadians. The government is contributing an estimated 50 % of the project's overall costs.

###

Ondine Biomedical Inc.

 

Angelika Vance, Corporate Communications

+001 (1) 604 838 2702

 

 

Strand Hanson Limited (Nominated and Financial Adviser)

 

James Harris, James Dance, Richard Johnson

+44 (0) 20 7409 3494

 

 

RBC Capital Markets

 

Rupert Walford, Kathryn Deegan

+44 (0) 20 7653 4000

 

Singer Capital Markets

 

Aubrey Powell, Asha Chotai

+44 (0)20 7496 3000

Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard

+44 (0) 77 1000 5910

 

Microbial foodborne disease

Foodborne illnesses are a major public health concern due to the high risk of microbial contamination of food. In 2010, more than 580 million illnesses and 351,000 deaths worldwide were associated with food contaminated by enteric pathogens according to a World Health Organization (WHO) estimate. Meat and meat-based products are particularly prone to contamination, accounting for more than 16% of total foodborne outbreaks in Europe in 2016.

Source: Int. J. Environ. Res. Public Health 2020, 17, 688; doi:10.3390/ijerph17030688

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. In addition to nasal photodisinfection (Ondine's lead product), products include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, wounds, and other indications related to healthcare associated infections.

 


[1] https://www.fao.org/in-action/seeking-end-to-loss-and-waste-of-food-along-production-chain/en/

[2] https://oem.bmj.com/content/78/7/530

[3] https://ondinebio.com/wp-content/uploads/2022/10/IPS-2022-Poster-Ondine-aPDT-against-clinical-isolates-of-MRSA-FINAL.pdf

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAMZMGZMDZGZZZ
Date   Source Headline
25th May 20237:00 amRNSResult of AGM
23rd May 20237:00 amRNSAnnual Report for the Year Ended 31 December 2022
10th May 20237:09 amRNSFull Year Results
3rd May 20233:30 pmRNSNotice of Results and Investor Presentation
3rd May 20238:02 amRNSNotice of AGM
3rd May 20237:56 amRNSIssue of Equity
20th Apr 202312:00 pmRNSOndine reports successful food pathogen study
18th Apr 202311:00 amRNSOndine Phase 2 results presented at ECCMID 2023
17th Apr 20237:00 amRNSProgress Update
5th Apr 20233:00 pmRNSOndine food-safe photodisinfection update
7th Mar 20237:00 amRNSLux Vitae advocates Steriwave for COVID prevention
3rd Mar 20237:00 amRNSOttawa hospital presents Steriwave study results
22nd Feb 20237:00 amRNSGrant of Share Options
31st Jan 202312:01 pmRNSOndine’s APDT reduces SARS-CoV-2 infectivity
17th Jan 202310:04 amRNSTR-1: Notification of major holdings
17th Jan 20239:30 amRNSNew photodisinfection study published
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
30th Dec 202212:31 pmRNSAppointment of Nominated Adviser
12th Dec 20227:00 amRNSSteriwave receives regulatory approval in Mexico
5th Dec 20227:00 amRNSOndine receives funding for meat photodisinfection
2nd Dec 20226:25 pmRNSOndine receives funding for meat photodisinfection
2nd Dec 20227:00 amRNSOndine reports full results from Phase 2 trial
21st Nov 20227:00 amRNSOndine appoints Spanish distributer for Steriwave
7th Nov 20229:02 amRNSOndine cuts COVID-19 rate in food processing plant
4th Nov 20227:00 amRNSPDMR Dealing
31st Oct 202211:18 amRNSOndine CTO receives Lifetime Achievement Award
28th Oct 20227:00 amRNSPDMR Dealing
19th Oct 202212:07 pmRNSOndine presents new efficacy data against MRSA
19th Oct 202211:36 amRNSSteriwave™ cuts SSI risk by 47% at major hospital
11th Oct 20227:00 amRNSInvestor Presentation
27th Sep 20227:00 amRNSInterim results for the six months to 30 June 2022
23rd Sep 20229:00 amRNSThe Ottawa Hospital pilots nasal disinfection
20th Sep 20229:34 amRNSNew research presented on photodisinfection
7th Sep 202212:30 pmRNSOndine’s photodisinfection kills ESKAPE pathogens
6th Sep 20227:00 amRNSOndine reports successful US Phase 2 trial data
31st Aug 202210:49 amRNSNature reports Ondine therapy suppresses COVID-19
16th Aug 20227:00 amRNSOndine appoints RBC and Singer as joint brokers
8th Aug 202210:02 amRNSOndine completes US Phase II trial recruitment
26th Jul 20227:00 amRNSCompletion of Nominated Adviser due diligence
22nd Jul 20227:00 amRNSIssue of Equity
19th Jul 20227:00 amRNSOndine completes successful SARS-CoV-2 trial
8th Jun 20227:00 amRNSResult of AGM
7th Jun 20227:00 amRNSPosting of annual report
19th May 20227:00 amRNSFull Year Results to 31 December 2021
17th May 20227:00 amRNSNotice of AGM
10th May 202210:30 amRNSWHO calls for better infection prevention
27th Apr 20224:30 pmRNSAppointment of Nominated Adviser
5th Apr 20227:00 amRNSPhotodisinfection effective against SARS-CoV-2
21st Feb 20227:00 amRNSGrant of Options and PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.